Chairman of the Board
Mr. Cohen previously served on the Board of Directors at the NYSE, as well as previously serving as the CEO and Chairman of the Board of Cowen Inc., Shearson Lehman, and Republic New York Securities. Mr. Cohen is currently a Trustee of Mount Sinai Medical Center, a Member of the Board of Directors of Quadrant Biosciences, Inc., and Vice Chairman and Lead Director of the Board of Directors of Scientific Games Corporation. Additionally, Mr. Cohen has previously served on a number of other corporate and industry boards, including The Federal Reserve International Capital Markets Advisory Committee, American Express, The Depository Trust Company, Telecom Italia SpA, Olivetti SpA, and Kroll Inc. He obtained a Masters of Business Administration from Columbia University in 1969 and a Bachelor of Science from The Ohio State University in 1968.
Willie Bogan, JD
Willie Bogan served as Associate General Counsel and Corporate Secretary of McKesson Corporation, a San Francisco-based healthcare services and information technology company, from July 2009 until his retirement in November 2015. He joined McKesson in November 2006 as Associate General Counsel and Assistant Secretary. Before joining McKesson, Mr. Bogan held senior advisory positions at four other public companies in the San Francisco Bay Area – Bank of America, Safeway, Charles Schwab and Catellus Development Corporation. Prior to becoming in-house counsel, he was a partner at Steinberg, Miller, Bogan & Goldstein in Manhattan Beach, California.During his tenure as a business and securities attorney, Mr. Bogan was involved in a variety of substantial commercial transactions and was an advisor to directors and executive management in the boardroom. Through this, Mr. Bogan acquired significant business and financial experience, including in relation to lending, borrowing, hedging, capital deployment, financial results, mergers and acquisitions, risks and risk management. Regarding healthcare, he acquired significant insight into supply chain systems and activities, and into the nature, opportunities and challenges of healthcare technology businesses. Mr. Bogan also has extensive corporate governance experience. Mr. Bogan graduated Phi Beta Kappa and Summa Cum Laude from Dartmouth College, where he majored in Spanish. He earned an MA degree in Politics and Economics from Oxford University, where he studied as a Rhodes Scholar, and a JD degree from Stanford Law School. While at Dartmouth, Mr. Bogan was an All-Ivy, All New-England, All-East and Academic-All American defensive back on the undefeated and nationally ranked 1970 football team and was drafted by the then Baltimore Colts. In addition, he was named a National Football Foundation and Hall of Fame scholar-athlete. In 1989, he was inducted into the Academic All-America Hall of Fame, an honor that recognizes former Academic All-Americans for career achievements.
Chris Nolet has served as a director and Chair of the Audit Committee at PolarityTE since April 2020. Mr. Nolet has extensive experience in audit with nearly 40 years in the profession. He is a retired audit partner at Ernst & Young where he was most recently the West Region Life Sciences Industry Leader. Prior to EY, Mr. Nolet spent over twenty years at PricewaterhouseCoopers, where he was a partner and led the North America West Life Sciences Industry Group. Mr. Nolet is currently a member of the Board of Directors of three publicly traded biotechnology companies, Viela Bio, Revance Therapeutics and Jasper Therapeutics, Inc. He is also a member of the Executive Committee and is Co-Chair of the Finance Committee of the California Life Sciences Industry Association (CLSA). Mr. Nolet is a former member of the Finance & Investment Committee and Emerging Companies Section of the Biotechnology Innovation Organization, and he has testified before Congress with Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research (CDER), regarding the need for FDA reform. Mr. Nolet holds a B.S. in Accounting from San Diego State University and is a Certified Public Accountant in California.
David Seaburg currently serves as Chair of the Board’s Strategic Review Committee and was previously a director from August 2018 to August 2019. Mr. Seaburg served as PolarityTE’s Chief Executive Officer from April 2020 through August 2021, President of Corporate Development from January 2019 to August 2019. During Mr. Seaburg’s tenure in management, the Company completed several significant restructuring initiatives, primarily focused on reducing costs, enhancing sales of SkinTE® when it was previously marketed as a 361 HCT/P, and preparing PolarityTE for the changes that would be required from a regulatory perspective for SkinTE following the conclusion of FDA’s period of enforcement discretion for 361 HCT/Ps in May 2021. Prior to PolarityTE, Mr. Seaburg spent roughly 25 years of his career at Cowen, Inc., a leading healthcare franchise in equities research, sales and investment banking. He was Managing Director, Head of Sales Trading and a member of the Cowen’s Equity Operating Committee, where he cultivated and led teams operating across multiple disciplines and specialties, leveraging human capital to drive the organization’s success. Over the course of his tenure, he interacted with thousands of healthcare investors and corporate management teams. Mr. Seaburg was also a CNBC Fast Money Contributor, where he provided regular on-air market commentary for the network.